arrow
M

Mahesh Parmar

university of london
H指数:103
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer

肿瘤增殖与转移性前列腺癌中对雄激素受体通路抑制的更高敏感性相关

2026-05-150
OA
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer

局部晚期前列腺癌的经皮雌二醇贴剂

2026-03-012
PRE
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial

多中心、随机、双盲、安慰剂对照、多臂、多阶段临床试验研究方案:评估螺内酯(SpironolacTone)和泛昔洛韦(famciclOovir)治疗进展性多发性硬化以预防残疾进展:STOP-MS试验

2025-12-010
OA
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性

Cell
IF42.5
2025-08-260
OAAI
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

二甲双胍用于开始接受雄激素剥夺治疗的转移性前列腺癌患者:一项STAMPEDE平台方案的随机III期试验

2025-07-070
OAAI
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

基于数字病理学的多模态人工智能衍生预后模型在开始长期雄激素剥夺治疗的晚期前列腺癌患者中的外部验证:STAMPEDE平台方案的四项Ⅲ期随机对照试验的回顾性附加生物标志物研究

2025-06-010
OAAI
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer. the STAMPEDE Phase 3 Randomized Clinical Trial

血浆AR改变及强化激素治疗前列腺癌的时机:STAMPEDE III期随机临床试验

2025-02-270
PRE
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)

根治性前列腺切除术后无,短期或长期雄激素剥夺疗法与术后放疗的随机试验: radical-hd的三向比较结果 (NCT00541047)

2024-11-011
OA
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)

根治性前列腺切除术 (RP) 后放疗 (RT) 的时机: radical-rt试验 (NCT00541047) 的长期结果

2024-07-019
OAAI
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

前列腺癌术后放疗的雄激素剥夺治疗持续时间: radical-hd随机试验中长疗程与短疗程雄激素剥夺治疗的比较

LANCET
IF88.5
2024-06-0113
PRE
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

在前列腺癌术后放疗中增加6个月的雄激素剥夺疗法: radical-hd随机对照试验中短程与无雄激素剥夺疗法的比较

LANCET
IF88.5
2024-06-0114
OAAI